about
PPARalpha deficiency in inflammatory cells suppresses tumor growth.Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect.A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient miceAdoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.Immunology and Immunotherapy of Head and Neck CancerLeukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention.The adaptive immune response to sporadic cancer.Tissue vaccines for cancer.Chemo-immunotherapy mediates durable cure of orthotopic KrasG12D/p53-/- pancreatic ductal adenocarcinomaIdentification of EpCAM as a molecular target of prostate cancer stroma.Interactions between the immune system and cancer: a brief review of non-spatial mathematical models.An anticancer strategic dilemma: to kill or to contain. The choice of the pharmaceutical industry in 2009.Tumor-associated macrophages as targets for tumor immunotherapy.Deciphering and reversing tumor immune suppression.Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.Targeting high-grade B cell lymphoma with CD19-specific T cells.Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.New developments in the management of head and neck cancer – impact of pembrolizumab.CTGF/VEGFA-activated fibroblasts promote tumor migration through micro-environmental modulation.Making and circumventing tolerance to cancer.Inhibitory effect of live-attenuated Listeria monocytogenes-based vaccines expressing MIA gene on malignant melanoma.Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy.
P2860
Q33275971-69EB925F-A82D-4A2E-9319-91AFBD9EA34EQ34027421-EBEEC2C7-E345-4067-B7D1-CD68ABE75BC3Q34412732-68EC4BD6-393F-4D7A-AFB8-9A73F48ACFBBQ35053317-6938817C-04AE-48D3-9562-598F8E55A40EQ35828752-8B4041E1-5A7A-4825-96BE-E57AD6D7AC8EQ36100837-6291C9E1-55B2-4D75-990E-FD5792702D40Q36568998-322251A3-445C-4EB1-8456-E46AE4749402Q36990593-57754328-8216-42CA-B527-E5D48BFE0122Q37123446-2D3EFDD8-5112-457C-A581-9C2413906330Q37308212-440EBC42-D35D-4DCC-94FE-008F6B0050F2Q37462612-B60F45E7-4113-4CBB-B329-53A14333FA32Q37708187-1F432DC0-DFFA-4186-BBFD-32826FB7D364Q37770597-B5239A87-A4A6-4ECE-9384-BB0FFE0D4A72Q37773280-C5D27A9E-1B4F-47D8-B59B-4B5FABFBABC0Q38124437-E13BAA15-4BCD-4BE3-9033-FCF651332559Q38953721-6BB104E7-E428-4ACD-87EB-D4E76663F1ACQ39026731-EE9FA238-5F16-4229-AD64-CD9356D8ACBFQ47259954-FEB841DE-8D81-497A-A3E0-39F32C317FB5Q50336126-9371210E-D1E9-47EE-8EF4-EC202FA17E10Q52579822-B3A65D1E-B117-462A-8EA2-BA4D16665DEAQ52909563-794D7DFE-A5A1-473A-9589-5C5C1EDC98B3Q54296972-569C507D-9119-4A0B-97F5-CF4531C69262Q55265767-DF714CD7-639C-4E13-AEE7-2758235C49F7Q55316070-0BF362CA-EA9D-45D0-B28C-7CC9782E9C24
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Immunotherapy: target the stroma to hit the tumor.
@ast
Immunotherapy: target the stroma to hit the tumor.
@en
type
label
Immunotherapy: target the stroma to hit the tumor.
@ast
Immunotherapy: target the stroma to hit the tumor.
@en
prefLabel
Immunotherapy: target the stroma to hit the tumor.
@ast
Immunotherapy: target the stroma to hit the tumor.
@en
P2093
P1476
Immunotherapy: target the stroma to hit the tumor.
@en
P2093
Thomas Blankenstein
Thomas Kammertoens
Thomas Schüler
P304
P356
10.1016/J.MOLMED.2005.03.002
P577
2005-05-01T00:00:00Z